Spectral Medical Inc T.EDT

I know we are not supposed to mention this, but...

[mercedesman]

Coronavirus: Kidney Damage Caused by COVID-19 | Johns Hopkins Medicine


Studies indicate more than 30% of patients hospitalized with COVID-19 develop kidney injury, and more than 50% of patients in the intensive care unit with kidney injury may require dialysis. 

I would venture to say, that it's not well understood by the market that Covid-19 could substantially increase the addressable market for BOTH PMX and DIALCO products.

And it's not just about saving lives, but also about the millions that have recovered from Covid-19 after being hospitalized, and also the long-Covid sufferors (even if Covid magically disappears, the legacy of organ injury remains)

While shareholders are not, I wonder if the potental suitors are suitably briefed on this seemingly material upside potential to LT revenues?

I noticed that the EBITDA analysis is still showing 120,000 addressable market based on 2016 CDC Sepsis stats.

Addressable market for DIMI I believe, is now showing a higher number.... $ 13 billion?  I wonder if that is becasue of Covid?  Or is that w/o factoring Covid (like in the case of PMX?)

What would a 10% market share for a game-changing technology get us?  My math says 1.3 billion USD ? ($ 1.62Million CAD $).  That's not including SAMI's addressable market btw.

MM

[JohnnyCashMoney]

Studies indicate you are a moron. I am good with a buy for .57/share.?

[Accountprince]

Thanks MM.  Nice to have you back posting again.  Raises the intellect level here dramatically.  Your calculated amount of $1.62 billion equates to over $5.00 per share for DIMI and that excludes the value for SAMI which could add a couple of dollars.  So $7.50 per share for Dialco is a real possible value. Perhaps the delay is initiating the 35 person trial is a function of

[mercedesman]

That's a good thought AP. FYI, Mgt. has estimated the'addresable market" for SAMI to be $ 280M, far less than the addressable market for the DIMI.  Although highly portable, and easy to use, it's not quite the "game-changer" that DIMI is believed to be. I would say there are at least 3 possible explanations for the protracted start date for the DIMI Trial 1.

[Domino55]

Hmmm MM/ makes you wonder what level of investor attention might befall EDT if the potential Covid angle was disclosed and or discussed in an investor presentation or NR. As far as I "officially" know Covid was a serious impediment to both trials and the subsequent cause of the recent and ongoing loss in market cap as a result of these delays. Anything more than that is speculation